LONDON (Alliance News) - AstraZeneca PLC said Friday that it had received a positive opinion from the EU's committee for medicinal products for human use for three of its treatments.
A positive opinion from the committee will be taken into account by the European Commission as part of its final decision on the products.
It received a positive opinion recommending the approval of Brilique for patients with a history of heart attack and high risk of a further atherothrombotic event.
Additionally, AstraZeneca received positive opinions recommending marketing authorisation for its adult gout treatment lesinurad, and Tagrisso for the treatment of T790M mutation positive non-small cell lung cancer.
Shares in AstraZeneca were down 1.2% at 4,382.00 pence Friday afternoon.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Astrazeneca (AZN)
